NAM has established a subsidiary in Italy named Sterion Italia S.r.l., with 100% ownership and registered capital of 20 million baht, to serve as a base for penetrating the European market and developing products that meet the region's high safety standards. Thailand remains the main production base, with positive results expected in the next two to three years. In the ASEAN market, the company exports to Malaysia and has begun SKD operations in Indonesia, while considering additional direct investment in the future. Currently, foreign revenue accounts for only 5% and is expected to increase significantly over the next three to five years. The company still targets total revenue growth of at least 10% this year from the previous year's 1.886 billion baht.
Namwiwat MedicalExpansion into European market via Italian subsidiary and potential further investment in Indonesia expected to significantly increase foreign revenue from current 5%.